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Dopamine D1 receptors within the basolateral amygdala mediate heroin-induced
conditioned immunomodulation
Abstract

This study investigates the role of basolateral amygdala (BLA) dopamine in heroin-induced
conditioned immunomodulation. Animals underwent conditioning in which heroin
administration was repeatedly paired with placement into a conditioning chamber. Six days after
the final conditioning session animals were returned to the chamber and received intra-BLA
microinfusions of dopamine, D1 or D2, antagonist. Antagonism of D1, but not D2, receptors
within the BLA blocked the suppressive effect of heroin-associated environmental stimuli on
iNOS, TNF-α and IL-1β. This study is the first to demonstrate that the expression of heroin's
conditioned effects on proinflammatory mediators require dopamine D1 receptors within the
BLA.
1. Introduction

The high rate at which heroin users contract opportunistic infections suggests that heroin use
may impair the ability of the host to combat infectious disease (Luttgens, 1949, Hussey & Katz,
1950, Louria et al., 1967). Although it has been postulated that this high rate of infection
amongst heroin users results from increased contact with pathogens, possibly through needle
sharing or impurities in street grade drugs, there is evidence that heroin may directly impact the
clinical course of infection (Kreek, 1990, Farizio et al., 1992, McLachlan et al., 1993) and
diseases associated with intravenous heroin use may be influenced by the ability of opioids to
modulate immune function (McDonough et al., 1980, Donahoe et al., 1986, Novick et al., 1989,

Oschorn et al., 1990). In fact, clinical studies report abnormalities in basic immune parameters in
heroin users, including decreased numbers of circulating lymphocytes, decreased NK cell
activity, and reduced antibody-dependent cellular cytotoxicity (Nair et al., 1986, Govitrapong et
al., 1998), suggesting that heroin may further contribute to increased infection susceptibility
among users, independently of concurrent risk factors. In further support of this, studies have
indicated that human heroin users exhibit poorer immune responses following hepatitis
vaccination (Quaglio et al., 2004, Rodrigo et al., 1992).

New studies in our laboratory have indicated that heroin induces alterations in a number of
immunological parameters including alterations in natural killer cell activity, T- and Blymphocyte proliferation, and nitric oxide production (Fecho et al., 2000, Lysle & How, 2000).
Nitric oxide is produced by many cells of the immune system and it mediates diverse biological
functions including vasodilation, the cytotoxic activity of macrophages, and the inhibition of
platelet adhesion and aggregation (Suschek et al., 2004, Tuteja et al., 2004). Opiate drug
administration has also been found to alter the production of several proinflammatory cytokines
including tumor necrosis factor-alpha (TNF-α) and interleukin-one beta (IL-1β) (Chao et al.,
1993, Benscsics et al., 1997, Pacifici et al., 2000, Clark et al., 2007). IL-1β and TNF-α both play
critical roles in the body's defense against infectious challenge, while also serving to regulate the
immune response to these challenges.

Previous research has shown that the effects of heroin on proinflammatory mediators (nitric
oxide, IL-1β and TNF-α) may be conditioned to environmental stimuli that have been associated
with drug administration (e.g., Lysle & Ijames, 2002, Szczytkowski & Lysle, 2007) and that

these conditioned effects are attenuated by inhibition of the basolateral amygdala (Szczytkowski
and Lysle, 2008). These findings suggest that the basolateral amygdala is an integral component
of the circuit mediating the conditioned effects of heroin on proinflammatory mediators. The
current study further explores the role of basolateral amygdala by examining the dopaminergic
inputs to this brain region and their involvement in the expression of heroin-induced conditioned
immunomodulation. Interestingly, the dopaminergic system within the BLA has been shown to
be involved in learning and memory and specifically the associative learning that underlies
classical conditioning. For example, intra-amygdalar 6-hydroxydopamine injections impaired
(Ashford and Jones, 1976), while post-training intra-BLA dopamine infusions enhanced
(LaLumiere et al., 2004) memory consolidation of a conditioned avoidance task. In addition, rats
with 6-hydroxydopamine lesions of the amygdala exhibit impaired acquisition of conditioning to
explicit cues (Selden et al., 1991). Microdialysis studies revealed an increase in dopamine and its
metabolites during the learning of a discriminative task in rats (Hori et al., 1993) further
supporting the importance of this neurotransmitter in BLA-mediated learning and memory.
Furthermore, Macedo et al. (2007) demonstrated that antagonism of dopamine D1 receptors
within the BLA reduces the expression of conditioned, but not unconditioned, fear.

Dopaminergic signaling within the BLA appears to be particularly important for the associative
learning processes that accompany the acquisition and expression of conditioned responses to
drugs of abuse. For example, intra-BLA administration of D-amphetamine potentiates cueinduced cocaine seeking possibly by increasing monoamine tone in this region (Ledford et al.,
2003). In addition, site specific administration of a dopamine D1/D2/D3 antagonist into the
basolateral amygdala, but not the central amygdala, blocks alcohol-induced conditioned place

preference in mice (Gremel and Cunningham, 2009). More specifically, stimulation of dopamine
D1 receptors in the BLA was found to be necessary for the expression of cue-induced
reinstatement of cocaine-seeking behavior in rats (See et al., 2001, Yun & Fields, 2003). In
contrast, dopamine D2 receptors in the BLA appear to be involved in the acquisition of
associations between drugs of abuse and the conditioned cues that guide subsequent cue-induced
drug-seeking behavior (Berglind et al., 2006). These findings provide a strong rationale for
examining the involvement of the dopaminergic system within the BLA on the expression of
heroin-conditioned immunomodulation.

The current set of experiments sought to establish the role of the dopaminergic system within the
basolateral amygdala in the conditioned effects of heroin on proinflammatory mediators. Rats
received five training sessions in which heroin was administered immediately upon placement
into a standard conditioning chamber which served as the conditioned stimulus (CS). On the test
day, the animals were re-exposed to the chamber for 60-min without drug administration and
given a subcutaneous injection of LPS (1000 μg/kg) upon removal. Immediately prior to CS
reexposure, animals received intra-BLA infusion of either saline vehicle, SCH23390 (dopamine
D1 receptor antagonist) or raclopride (D2 antagonist) to determine the role of dopamine
signaling in heroin-induced conditioned immunomodulation. The findings reported here are
important because they indicate that previously heroin-associated environmental stimuli are not
only capable of inducing alterations in proinflammatory mediators but that these effects may be
modified by antagonism of specific dopaminergic receptors within the BLA.
2. Materials and methods
2.1. Animals

Male Lewis rats, weighing 225–250 g, were purchased from Charles River Laboratories
(Raleigh, N.C., USA). Upon arrival, animals were housed individually in plastic cages in a
colony room with a reversed light–dark (12 h) cycle maintained through artificial illumination.
Animals were allowed access to food and water ad libitum throughout the experiment except for
the time spent in the conditioning chambers when food and water were not available. All animals
were given a 2-week habituation period before the start of experimental manipulations and were
handled regularly during this time. All procedures described were approved by the IACUC of the
University of North Carolina at Chapel Hill and conformed to National Institutes of Health
(NIH) Guidelines on the Care and Use of Laboratory Animals.
2.2. Drug administration

Heroin (diacetylmorphine) was obtained from NIDA (Bethesda, MD) and dissolved in 0.9%
sterile saline. For all experiments, animals received a subcutaneous injection of heroin at a dose
1 mg/kg immediately prior to placement in the conditioning chamber on each of the five
conditioning trial days. This dose was selected based on prior experiments in our laboratory
showing that a 1 mg/kg dose of heroin alters LPS-induced iNOS, IL-1β and TNF-α mRNA
expression in spleen and liver tissue and induces conditioning (Lysle & How, 2000, Lysle &
Ijames, 2002, Szczytkowski & Lysle, 2007).
2.3. Surgery and microinjection

Animals were anesthetized with 0.35 ml intramuscular injections of 1:1 (vol/vol) ketamine
hydrochloride (100 mg/ml) mixed with xylazine (20 mg/ml) and placed into the stereotaxic

apparatus. Animals were implanted with 26-gauge bilateral guide cannula (Plastics One,
Roanoke, VA) directed towards the BLA (AP − 2.5, ML ± 5.0, DV − 6.6). Coordinates are
expressed as millimeters from bregma (Paxinos and Watson, 1986).

Animals were given a two week recovery period before the start of conditioning trials. On test
day, animals received bilateral intracranial injections (0.5 μl/side infused over 1 min) of saline
vehicle, the D1 antagonist, SCH23390 (2 μg/0.5 μl/side) or the D2 antagonist, raclopride (5
μg/0.5 μl/side) 30 min prior to re-exposure to the conditioning chambers. Antagonist doses were
chosen based upon previous behavioral studies that had shown reductions in cue-induced drug
seeking following administration of these doses into the BLA (Berglind et al., 2006, See et al.,
2001). Injectors extended 2 mm beyond the tip of the cannula and were left in place for 1 min
after the injection to allow for proper infusion.
2.4. Histology

To confirm proper cannula placement Alcian blue dye was infused via the cannula following
sacrifice. Brains were then extracted and post-fixed in a 4% paraformaldehyde solution.
Following fixation the brains were transferred to a 30% sucrose solution for cryoprotection and
then frozen at − 80 °C until further analysis. Coronal sections (50 μm) were taken and stained
with cresyl violet for verification of cannula placement. Animals with cannula placement outside
of the targeted region were removed from the analyses.
2.5. Procedures
2.5.1. Acquisition of conditioned response

To condition heroin's effects on iNOS expression, all animals received five 60-min training
sessions in which they received a subcutaneous injection of heroin upon placement into a
standard conditioning chamber. Training sessions were separated by 48 h. The conditioning
chambers (BRS/LVE, Laurel, MD, USA) were contained in a room separate from the animal
colony and contained a metal grid floor design and cedar bedding to create an environment
distinct from that of the home cage. All conditioning took place during the dark phase of the light
cycle, and the conditioning chambers were kept dark.
2.5.2. Testing of expression of conditioned response

The test day took place six days following the final conditioning session. To test the expression
of the conditioned response, animals were re-exposed to the conditioned stimulus (i.e.; the
conditioning chambers) without drug to determine whether the conditioned stimulus alone would
induce alterations in pro-inflammatory mediators. Thirty minutes prior to testing, animals
received intra-BLA microinfusions of either the D1 antagonist, SCH23390, or the D2 antagonist,
raclopride. Control animals received intra-BLA microinfusions of saline vehicle. Two groups of
animals were then re-exposed to the chambers (conditioned stimulus, CS) for 60-min without
further administration of heroin. The remaining animals (home cage, HC) were returned to the
home cage following microinfusions and served as controls. After the 60-min re-exposure, the
animals were removed from the chambers and given a subcutaneous injection of LPS (1000
μg/kg) to induce iNOS, TNF-α and IL-1β production. Home cage animals also received LPS at
this time. Six hours after LPS administration all animals were sacrificed and samples of spleen,
liver and blood were collected for analysis. Spleen and liver tissue were collected as
immunohistochemical localization of iNOS in rats exposed to LPS has shown the presence of the

iNOS enzyme in a number of immune cells in a variety of tissues including eosinophils within
the spleen and Kupffer's cells and hepatocytes within the liver (Bandaletova et al., 1993). The 6h timepoint was selected based on previous research in our laboratory showing maximal iNOS
induction at 6 h following LPS administration (Lysle and How, 2000).
2.6. Real time RT-PCR

To determine iNOS expression, real time RT-PCR was performed on tissue samples from the
spleen and liver. Total RNA was extracted from a section of each of the tissues using TRIReagent (Molecular Research Center, Cincinnati, OH), a modification of the original method
described by Chomczynski and Sacchi (1987). RNA was quantified spectrophotometrically
(GeneQuant II, Pharmacia-Biotech, Piscataway, NJ, USA). For the RT-PCR, reverse
transcription is performed using Oligo(dT)18 primer and Moloney Murine Leukemia VirusReverse transcriptase following the protocol of the Advantage RT-for-PCR Kit from Clontech
(Palo Alto, CA, USA).

PCR amplifications were performed using the Fast StartTM DNA Master SYBR Green I RealTime PCR Kit (Roche) and the LightCycler instrument (Roche). A master mix containing all
reaction components was prepared for all reactions, with each reaction using a 20 ml mix placed
in glass capillary tubes specifically designed for use in the LightCycler system. The PCR primer
set for iNOS, 5′-CCCTTCCGAAGTTTCTGGCAGCAGC-3′ and 5′-GGGTGTCAGAGTCTTGTGCCTTTGG-3′ was synthesized by the Nucleic Acids Core Facility (Lineberger
Cancer Center, UNC-Chapel Hill). Copy numbers were generated from an external standard
curve. Amplifications were carried out for 40 cycles and curves showing fluorescence at each

cycle were determined by the computer software (Roche). Samples were pre-incubated for 10
min at 95 °C to activate the Fast-Start Taq DNA polymerase. The cycle temperatures were 95,
60, and 72 °C for the denaturing, annealing, and extending, respectively. The cycle times were
15, 5, and 25 s for the denaturing, annealing, and extending, respectively. Flourescence level was
determined at the end of the extending phase for each cycle of PCR. The analysis of the
fluorescence level in standards and samples over the course of 40 cycles was used to derive the
number of copies of the target molecule in each sample. Additionally, assessments of
housekeeping gene expression, cyclophilin, were made to assure comparable quality of RNA
among samples. The sequence of the cyclophilin primers was 5′-CCAAGACTGAGTGGCT-3′
and 5′-AGATTACAGGGTATTGCG-3′. The data are expressed as a copy number of iNOS (per
10 ng cDNA) based on the standard curve using the Lightcycler software (Roche).

Furthermore, to confirm the nature of amplification product, a melt curve analysis was conducted
after the final PCR cycle. This analysis involved denaturing the products by slowly heating them
to 95 °C, during which fluorescence is continuously measured.
2.7. ELISA

For IL-1β and TNF-α protein determinations, protein was extracted from a section of each
homogenized tissue using freeze/thaw lysis in tris-buffer containing antiproteinases. Protein was
quantified spectrophotometrically (Bio-Tek, Model EL312 kinetic reader, Winooski, VT, USA)
using Bio-Rad protein dye. To account for variability in tissue size, samples were normalized per
unit protein based on the results of the spectrophotometric analysis. The BioSource International,
Inc. (Carlsbad, CA) rat IL-1β and TNF-α ELISA test kits were used to determine the levels of

IL-1β or TNF-α protein in each tissue sample. Briefly, samples and standards were added to
microtiter wells coated with antibody that recognizes IL-1β or TNF-α and incubated at room
temperature. Wells were washed extensively and then incubated with biotinylated antibody,
followed by a second wash and then incubation with Streptavidin-HRP. After the final washing,
a chromagen substrate solution was added which reacted with the bound enzyme to produce
color. The color intensity developed proportionally to the amount of IL-1β or TNF-α present in
each sample. The enzyme reaction was stopped after 30 min, and the absorbance at 450 nm was
measured with a Bio-Tek (Winooski, VT) Model EL312 kinetic reader. A standard curve was
obtained by plotting the absorbance versus the corresponding concentrations of the supplied
standards.
2.8. Nitrite/nitrate assay

The level of nitrite/nitrate in plasma samples was assessed using the Greiss reagent assay. Nitrate
and nitrite are formed non-enzymatically when nitric oxide is exposed to oxygen, thus plasma
levels of these products indicate the level of nitric oxide production. Total nitrite/nitrate levels is
determined by the conversion of nitrate to nitrite utilizing nitrate reductase in the presence of
NADPH and flavin adenine dinucleotide, and then an assessment using Greiss reagent. Briefly, 6
μl of plasma diluted in 44 μl of dH2O is incubated for in the dark for 90-min with 10 μl of nitrate
reductase (1.0 unit/ml), 20 μl of a 0.31 M phosphate buffer (ph 7.5), 10 μl of 0.86 mM NADPH
(Sigma), and 10 μl of a 0.11 mM flavin adenine dinucleotide in individual wells of a 96-well
plate. Then, 200 ml of Griess reagent consisting of a 1:1 (v/v) solution 1% sulfanilamide in 5.0%
phosphoric acid and 0.1% N-(1-napthyl)ethyl-enedamine dihydrochloride in distilled water was
added to the samples. The color developed for 10 min at room temperature after which the

absorbance was determined using a spectrophotometer set at 550 nm. All reactions were carried
out in triplicate. The total micromolar concentration of nitrite is determined for each sample
based on a standard curve. Recovery of nitrate is greater than 95% using this assay.
2.9. Statistical analysis

Analysis of variance was performed on all data sets. When the overall ANOVA showed
significant effects, post hoc comparisons were made using Tukey's test to compare individual
treatment groups to the home cage control. All analyses were conducted with the level of
significance set at p < 0.05.
3. Results
3.1. D1 receptor antagonism

The first study investigated the effect of intra-BLA microinfusion of the D1 receptor antagonist,
SCH23390, on the expression of heroin-induced conditioned suppression of proinflammatory
mediators. Six days following the final conditioning session, animals were divided into groups
with one group being re-exposed to the previously heroin-paired environment for 60 min (CS
Exposed) while the control groups remained in the home cage. In order to temporarily block the
receptors under investigation, animals in the SCH23390 groups received microinfusions of the
SCH23390 compound directly into the BLA 30 min prior to testing of the conditioned response.
The animals in the saline-treated groups received microinfusions of saline into the BLA.

Fig. 1 shows the mean levels of LPS-induced iNOS mRNA expresssion in the spleen and liver
for each group of animals. Analysis of iNOS copy number in spleen and liver, respectively,

revealed a significant main effect of group [F(3,15) = 9.885, P < 0.01; F(3,15) = 16.883, p <
0.01]. Moreover, post-hoc analyses revealed a significant difference in iNOS mRNA copy
number between the saline-treated animals exposed to the conditioned stimulus on test day
(Saline, white bar) and the animals who remained in the home cage on test day (Saline, black
bar). These differences were evident in both tissues (p < 0.05) which reconfirms our earlier
findings indicating that exposure to a previously heroin-paired environment suppresses the
expression of iNOS mRNA. Most importantly, there were no significant differences between the
saline-treated control group (Saline, black bar) and the SCH23390-treated CS-exposed group
(SCH23390, white bar) for either tissue. These results demonstrate that antagonism of dopamine
D1 receptors in the BLA blocks the conditioned effects of a previously heroin-paired
environment on iNOS mRNA expression.

Fig. 1. Effect of treatments on LPS-induced expression of iNOS mRNA in the spleen and liver as
determined by real-time RT-PCR. Exposure to the conditioned stimulus (Saline, white bar)
resulted in a conditioned suppression of iNOS mRNA in both the spleen and liver. Intra-BLA
microinfusion of the D1 receptor antagonist SCH23390 blocked the effect of the conditioned
stimulus (SCH23390, white bar). Data are expressed as iNOS copy number per 10 ng cDNA
based on a standard curve using Roche LightCycler software.

The data in Fig. 2 show levels of serum nitrite/nitrate levels for each group. The ANOVA
revealed a significant main effect of procedure [F(3,15) = 10.789, P < 0.01] on the levels of

nitrite/nitrate in the serum. Post-hoc analyses revealed a significant difference between the
saline-treated animals exposed to the conditioned stimulus on test day (Saline, white bars) and
the animals who remained in the home cage on test day (Saline, black bars) (p < 0.05). These
results further support our earlier findings that exposure to a previously heroin-paired
environment decreases serum nitrite/nitrate levels, indicating a reduction in nitric oxide
production. There were no significant differences between the SCH23390-treated group exposed
to the conditioned stimulus on test day (SCH23390, white bar) and the saline-treated control
group (Saline, black bar) indicating that the antagonism of dopamine D1 receptors in the BLA
attenuated the conditioned response. There were also no differences between the saline-treated
control group (Saline, black bar) and the SCH23390-treated control group (SCH23390, black
bar) indicating that administration of SCH23390 alone does not alter nitrate levels in the serum.

Fig. 2. Effect of treatments on serum nitrite/nitrate levels as determined by the Greiss reagent
assay. Animals exposed to the conditioned stimulus on test day (Saline, white bar) exhibit a
conditioned suppression of serum nitrite/nitrate concentration. This suppression is blocked by
intra-BLA infusion of the dopamine D1 receptor antagonist SCH23390 (SCH23390, white bar).
The data are expressed as the micromolar concentration of nitrite/nitrate.

Fig. 3 illustrates that the suppressive effect of heroin on mRNA and protein levels of the proinflammatory cytokine, IL-1β, can be conditioned to environmental stimuli and this conditioned
effect may be reduced by antagonism of dopamine D1 receptors within the BLA. Analysis

revealed a significant main effect of treatment on mRNA levels in the spleen [F(3,15) = 6.794, p
< 0.01] and liver [F(3,15) = 8.929, p < 0.01] as well as a main effect of treatment on protein
levels in the spleen [F(3,15) = 7.873, p < 0.01] and liver [F(3,15) = 3.694, p < 0.05]. In line with
our previous experiments, the saline-treated conditioned group exposed to the CS (Saline, white
bar) exhibited significantly lower levels of IL-1β mRNA and protein in both the spleen and liver
(p < 0.05) as compared to the saline-treated home cage control group (Saline, black bar). Most
importantly, the SCH23390-treated CS-exposed group (SCH23390, white bar) was not
significantly different from the saline-treated home cage control group (Saline, black bar) for
either tissue indicating that inactivation of the BLA was able to attenuate the conditioned effects
of heroin on IL-1β. There were also no significant differences between the SCH23390-treated
control group and the saline-treated control group indicating that SCH23390-treatment alone did
not have an effect on IL-1β mRNA or protein levels in the spleen or liver.

Fig. 3. Effect of treatments on LPS-induced expression of IL-1β mRNA and protein in the spleen
and liver as determined by real-time RT-PCR and ELISA. CS-exposed animals (Saline, white
bar) exhibit a conditioned suppression in both IL-1β mRNA and protein in both the spleen and
liver that is blocked by intra-BLA administration of the D1 receptor antagonist, SCH23390
(SCH23390, white bar). mRNA data are expressed as IL-1β copy number per 10 ng cDNA based
on a standard curve using Roche LightCycler software. ELISA data are expressed as pg of
cytokine protein per mg of total protein.

Fig. 4 shows that the suppressive effect of heroin on the proinflammatory cytokine, TNF-α, may
be conditioned to environmental stimuli and, again, this conditioned effect is reduced by
antagonism of dopamine D1 receptors within the BLA. This effect was evident at the mRNA and
protein level in both spleen and liver tissue. Analysis revealed a main effect of treatment on
mRNA and protein, respectively, in both spleen [F(3,15) = 6.415, p < 0.01; F(3,15) = 9.027, p <
0.01] and liver [F(3,15) = 7.313, p < 0.01; F(3,15) = 9.996, p < 0.01]. In line with our previous
experiments, the saline-treated group exposed to the conditioned stimulus on test day exhibited
significantly lower levels of TNF-α mRNA and protein in the spleen and liver (p < 0.05) when
compared to the saline-treated home cage control group. In addition, there were no significant
differences between the saline-treated home cage control group and either of the SCH23390treated groups.

Fig. 4. Effect of treatment on LPS-induced expression of TNF-α mRNA and protein in the spleen
and liver as determined by real-time RT-PCR. Animals re-exposed to the CS on test day (Saline,
white bars) exhibited a conditioned suppression of TNF-α mRNA and protein that was blocked
by D1 receptor antagonism within the BLA (SCH23390, white bars). PCR data are expressed as
TNF-α copy number per 10 ng cDNA based on a standard curve using Roche LightCycler
software. ELISA data are expressed as pg of cytokine protein per mg of total protein.
3.2. D2 receptor antagonism

The second study investigated the effect of intra-BLA microinfusion of the D2 receptor
antagonist, raclopride, on the expression of heroin-induced conditioned suppression of
proinflammatory mediators. The experimental design followed that of the D1 receptor antagonist
study with one group being re-exposed to the previously heroin-paired environment for 60 min
on test day while the control groups remained in the home cage. In order to temporarily block the
dopamine D2 receptors within the BLA, animals in the raclopride-treated groups received
microinfusions of the D2 antagonist directly into the BLA 30 min prior to testing of the
conditioned response. The animals in the saline-treated groups received microinfusions of saline
into the same area.

Fig. 5 shows the mean levels of LPS-induced iNOS mRNA expresssion in the spleen and liver
for each group of animals. Analysis of iNOS copy number in spleen and liver, respectively,
revealed a significant main effect of group [F(3,15) = 7.173, P < 0.01; F(3,15) = 7.816, p < 0.01].
Moreover, post-hoc analyses revealed a significant difference in iNOS mRNA copy number
between the saline-treated animals exposed to the conditioned stimulus on test day (Saline, white
bars) and the animals who remained in the home cage on test day (Saline, black bars). These
differences were evident in both tissues (p < 0.05) which reconfirms our earlier findings
indicating that exposure to a previously heroin-paired environment suppresses the expression of
iNOS mRNA. Interestingly, there was also a significant difference between the saline-treated
home cage control group (Saline, black bars) and the raclopride-treated CS-exposed group
(Raclopride, white bars) for both tissues. These results indicate that antagonism of dopamine D2
receptors in the BLA does not alter the conditioned effects of a previously heroin-paired
environment on iNOS mRNA expression.

Fig. 5. Effect of treatments on LPS-induced expression of iNOS mRNA in the spleen and liver as
determined by real-time RT-PCR. CS exposure (Saline, white bars) significantly reduced iNOS
mRNA in both the spleen and liver and this effect was not blocked by intra-BLA D2 receptor
antagonist administration (Raclopride, white bars). Data are expressed as iNOS copy number per
10 ng cDNA based on a standard curve using Roche LightCycler software.

The data in Fig. 6 show the mean levels of serum nitrite/nitrate for each experimental group. The
ANOVA revealed a significant main effect of procedure [F(4,15) = 8.295, P < 0.05] on serum
levels of nitrite/nitrate. Post-hoc analyses revealed a significant difference between the salinetreated animals exposed to the conditioned stimulus on test day (Saline, white bar) and the
animals who remained in the home cage (Saline, black bar) (p < 0.05). These results are in line
with our earlier experiments demonstrating that the suppressive effect of heroin on serum
nitrite/nitrate levels may be conditioned to environmental stimuli. There was also a significant
difference between the raclopride-treated group exposed to the conditioned stimulus on test day
(Raclopride, white bar) and the saline-treated home cage control group (Saline, black bar)
indicating that antagonism of dopamine D2 receptors within the BLA does not have an effect on
the conditioned response to a previously heroin-paired environment.

Fig. 6. Effect of treatments on serum nitrite/nitrate levels as determined by the Greiss reagent
assay. Exposure to the CS on test day resulted in a conditioned suppression of serum
nitrite/nitrate levels (Saline, white bar) that was not affected by intra-BLA raclopride (D2
antagonist) administration (Raclopride, white bar). Data are expressed as the micromolar
concentration of nitrite/nitrate.

Fig. 7 shows that the suppressive effect of heroin on mRNA and protein levels of the proinflammatory cytokine, IL-1β, can be conditioned to environmental stimuli and this conditioned
response is not altered by antagonism of dopamine D2 receptors within the BLA. Analysis
revealed a main effect of treatment on IL-1β mRNA levels in the spleen [F(3,15) = 18.94, p <
0.01] and liver [F(3,15) = 5.601, p < 0.05] as well as protein levels in the spleen [F(3,15) =
34.440, p < 0.01] and liver [F(3,15) = 50.416, p < 0.01]. In line with our previous experiments,
the saline-treated CS-exposed group exhibited significantly lower levels of IL-1β mRNA and
protein in the spleen and liver (p < 0.05) as compared to the saline-treated home cage control
group. Most importantly, the raclopride-treated CS-exposed group (Raclopride, white bars) also
displayed significantly lower levels of IL-1β mRNA in the spleen and liver as compared to the
saline-treated home cage control group (Saline, black bars). These data suggest that antagonism
of dopamine D2 receptors within the BLA does not alter the conditioned effects of heroin on IL1β mRNA levels. There were also no significant differences between the raclopride-treated home
cage control group and the saline-treated home cage control group indicating that raclopridetreatment alone did not have an effect on IL-1β mRNA or protein levels in the spleen or liver.

Fig. 7. Effect of treatments on LPS-induced expression of IL-1β mRNA in the spleen and liver as
determined by real-time RT-PCR and IL-1β protein levels as determined by ELISA. Exposure to
the CS on test day resulted in a suppression of IL-1b copy number and protein levels in both the
spleen and liver (Saline, white bars). Antagonism of dopamine D2 receptors within the BLA did
not block this effect (Raclopride, white bars). PCR data are expressed as IL-1β copy number per
10 ng cDNA based on a standard curve using Roche LightCycler software. ELISA data are
expressed as pg of cytokine protein per mg of total protein.

Fig. 8 shows that the heroin-induced conditioned suppression of the proinflammatory cytokine,
TNF-α, is not affected by antagonism of dopamine D2 receptors within the BLA. Analysis
revealed a main effect of treatment on mRNA and protein in the spleen [F(3,15) = 10.23, p <
0.01; F(3,15) = 6.567, p < 0.05] and on mRNA in the liver [F(3,15) = 18.936, p < 0.01]. In line
with our previous experiments, the saline-treated group exposed to the conditioned stimulus on
test day (Saline, white bars) exhibited significantly lower levels of TNF-α mRNA and protein in
the spleen and TNF-α mRNA in the liver (p < 0.05) when compared to the saline-treated home
cage control group (Saline, black bars). In addition, the raclopride treated group that was reexposed to the conditioned stimulus on test day (Raclopride, white bars) also exhibited a
conditioned reduction in TNF-α mRNA and protein in the spleen and mRNA in the liver as
compared to the saline-treated control group (p < 0.05). TNF-α mRNA levels in the liver showed
this same trend, however, ANOVA revealed this was not statistically significant.

Fig. 8. Effect of treatments on LPS-induced expression of TNF-α mRNA and protein in the
spleen and liver as determined by real-time RT-PCR. Animals re-exposed to the conditioned
stimulus (Saline, white bars) showed a conditioned suppression in TNF-α mRNA and protein
that was not altered by intra-BLA raclopride treatment (Raclopride, white bars). The PCR data
are expressed as TNF-α copy number per 10 ng cDNA based on a standard curve using Roche
LightCycler software. ELISA data are expressed as pg of cytokine protein per mg of total
protein.
4. Discussion

The findings presented here demonstrate that dopamine within the basolateral amygdala plays a
critical role in the conditioned effects of heroin on proinflammatory mediators. Specifically,
these results revealed that antagonism of dopamine D1 receptors within the BLA blocks the
expression of heroin-induced conditioned suppression of nitric oxide, TNF-α and IL-1β. The
SCH23390 compound has been used extensively as a selective D1 receptor antagonist and the
dose of 2.0 μg/side was chosen based upon an established literature showing an effect of this
dose administered intra-BLA on cue-induced reinstatement to drug seeking (Berglind et al.,
2006, Alleweireldt et al., 2006). Interestingly, selective antagonism of dopamine D2 receptors
within this same region does not appear to have any effect as the animals exposed to the
conditioned stimulus and administered the antagonist still exhibited a conditioned suppression in
proinflammatory mediators. Collectively, these data indicate a role for dopamine D1, but not D2,
receptors in the expression of heroin-induced conditioned immunomodulation. These data are in
line with similar studies demonstrating that intra-accumbens SCH23390 blocks the effects of

opioid drugs, and stimuli associated with opioid drugs, on NK cell activity and nitric oxide
production (Saurer et al., 2006a, Saurer et al., 2006b, Saurer et al., 2009).

The mesolimbic dopamine system is known to be critically involved in the expression of the
rewarding properties of drugs of abuse, including opiates. In fact, heroin administration
indirectly induces increased dopamine by the binding of its metabolites to mu-opioid receptors
on GABA-ergic neurons within the ventral tegmental area. Dopamine has also been widely
implicated in the formation of memories underlying associative learning processes. Specifically,
dopamine and its receptors have been shown to mediate the learning of associations between
drugs of abuse and their conditioned cues and antagonism of dopamine receptors may interfere
with the acquisition or retrieval of reward-related memories. For example, microdialysis studies
revealed an increase in dopamine and its metabolites during the learning of a discriminative task
in rats (Hori et al., 1993) and upon the presentation of a stimulus that had previously been paired
with cocaine administration (Weiss et al., 2000). In addition, intra-amygdalar 6hydroxydopamine injections impaired (Ashford and Jones, 1976), while post-training intra-BLA
dopamine infusions enhanced (LaLumiere et al., 2004) memory consolidation of a conditioned
avoidance task. Furthermore, intra-BLA infusions of amphetamine were found to potentiate cueinduced drug-seeking behavior following extinction (Ledford et al., 2003). Taken together, these
data suggest a role for dopamine in the BLA in heroin-induced classically conditioned immune
alterations either through the mediation of neuroimmune pathways or indirectly through the
alteration of learning/memory processes.

The study of classical or Pavlovian conditioning allows for the dissociation of the associative
processes underlying the acquisition of a learned response from the mechanistic control of the
expression of the response itself. In many cases these two phenomena are controlled via separate
mechanisms. For example, antagonism of beta-adrenergic receptor activity disrupts the
expression but not the acquisition of conditioned morphine-induced immune alterations
(Coussons et al., 1994). The data reported here suggest that dopamine D1 receptors within the
BLA are required for the expression of heroin's conditioned effects on proinflammatory
mediators. However, it is unknown whether D1 receptors within the BLA might also be involved
in the acquisition of these responses and this presents an important area for future investigation.
Interestingly, there appears to be differential involvement of dopamine receptor subtypes within
the BLA in the acquisition and the expression of responses to conditioned drug cues. Several
subtypes of dopamine receptors have been characterized and the BLA has been shown to express
both D1- and D2-like receptors (Meador-Woodruff et al., 1991, Scibilia et al., 1992). Macedo et
al. (2007) demonstrated that antagonism of dopamine D1 receptors within the BLA reduces the
expression of conditioned, but not unconditioned, fear. In addition, stimulation of dopamine D1
receptors in the BLA is necessary for the expression of cue-induced reinstatement of cocaineseeking behavior in rats (e.g., See et al., 2001, Yun & Fields, 2003). In contrast to the role of D1
receptors, D2 receptors in the BLA appear to be involved in the acquisition of associations
between drugs and their cues. For example, blocking dopamine D2 receptors in the BLA during
the acquisition phase of conditioning results in alterations in the reinstatement of cue-induced
cocaine-seeking behavior (Berglind et al., 2006). There has also been evidence for the
involvement of dopamine D3 receptors within the BLA in reward learning as antagonism of
these receptors was found to block reinstatement of drug seeking under a second-order schedule

of reinforcement (Di Ciano, 2008). Based on the evidence from these studies it might also be
important to examine the potential role of dopamine D2 and D3 receptors in the acquisition of
associations between heroin and heroin-related cues that elicit immunomodulation.

The BLA receives many of its dopaminergic inputs from the ventral tegmental area (VTA) and
substantia nigra as one of the main targets of the mesolimbic dopamine system (Rosenkranz and
Grace, 1999). These inputs appear to be important for learning to associate the rewarding
properties of drugs of abuse with external cues resulting in the ability of these drug cues to
induce relapse to drug-seeking and other conditioned behaviors (Di Ciano & Everitt, 2005, See,
2005). The data reported here suggest that opioids and opioid-associated drug cues induce
dopamine release from neurons originating in the VTA which then binds to D1 receptors located
within the BLA to influence the expression of conditioned responses to heroin related cues.
Research has shown that the primary targets of mesolimbic dopaminergic neuron inputs to the
BLA are the dendrites of the pyramidal neurons (Muller et al., 2009). Within the BLA there exist
two distinct neuronal cell populations, pyramidal and non-pyramidal neurons. The pyramidal
neurons of the BLA primarily utilize glutamate as their neurotransmitter and exhibit spiny
projections while the non-pyramidal cells rely heavily upon inhibitory GABA signals and show
fewer spines (McDonald, 1992). Dopamine selectively increases the excitability of BLA
pyramidal neurons allowing for potentiation of the inputs from other brain regions, such as the
cortex (Pickel et al., 2006). Interestingly, the pyramidal cell glutamatergic projections from the
BLA have been shown to synapse in close proximity to dopamine axons on medium spiny
neurons of the nucleus accumbens (Johnson et al., 1994, Kelley et al., 1982, Robinson & Beart,
1988) thus giving rise to a complex interaction between dopamine and glutamate within these

two brain regions. In addition, electrophysiological studies have shown that tetanic stimulation of
the BLA evokes dopamine efflux in the nucleus accumbens via glutamate receptor-dependent
mechanisms localized within the accumbens (Floresco et al., 1998). Furthermore, either
exogenously applied or synaptically released dopamine can modulate excitatory responses of
nucleus accumbens neurons evoked by low frequency stimulation of the BLA (Yim and
Mogenson, 1986). Collectively, these data suggest that the circuit encompassing the VTA, BLA
and nucleus accumbens may be involved in the conditioned effects of heroin on immune
measures.

While it appears that the BLA does not directly impact immune functioning it is highly plausible
that conditioned immune alterations may be induced through the connections of the BLA with
the nucleus accumbens. Saurer et al. (2006a) demonstrated that intra-accumbens shell
administration of a dopamine D1 agonist resulted in decreased NK cell activity indicating that
dopamine activity within the accumbens is sufficient for expression of heroin-induced
conditioned immunomodulation. It is as yet unknown what factors may be mediating these
effects in the periphery but there is a wealth of data suggesting that the sympathetic nervous
system may be involved. For example, both primary and secondary lymphoid tissues have been
found to be innervated by the sympathetic nerve fibers (Williams et al., 1981, Felten et al., 1984)
and adrenergic receptors have been identified on the surface of immune cells (Livnat et al., 1985,
Hori et al., 1995, Maestroni, 2006). More specifically, peripheral administration of β-adrenergic
antagonists has been shown to block the expression of the conditioned effects of morphine on
several measurements of immune status (Coussons et al., 1994). However, it appears that at least
some of these immune alterations are mediated peripherally by neuropeptide Y as systemic

administration of a neuropeptide Y Y1 receptor antagonist dose-dependently attenuates
morphine-induced alterations in NK cell activity while β-adrenergic antagonism had no effect
(Saurer et al., 2006b). These data seem to suggest differential mechanisms for the control of
specific opioid-induced immune alterations.

It is imperative to understand the mechanisms by which heroin-induced conditioned
immunomodulation occurs as these effects may have widespread implications for the health of
recovering opiate users. Nitric oxide, TNF-α and IL-1β are all components of the innate immune
response that play critical roles in the host's initial response to pathogenic challenge. In the
absence of a proper immune response, such as occurs following exposure to drug-related cues,
the host's immune system may not be able to adequately deal with infection. This disruption of
immune functioning may allow for increased pathogenic proliferation which may progress to
sepsis. The exact neural mechanism through which heroin-induced conditioned
immunomodulation occurs is still not fully understood, but the data presented here suggests that
the BLA plays a critical role. The experiments reported here are the first to identify the
dopaminergic D1 receptors within the BLA as crucial for the expression of the effects of heroinrelated cues on immune functioning.
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